60 and older, female only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in C-terminal Telopeptide of Type I Collagen [CTX]Primary· Baseline, 20 weeks
Percent change in serum bone turnover markers C-terminal telopeptide of type I collagen \[CTX\]. The C-terminal telopeptide (CTX), also known as carboxy-terminal collagen crosslinks, is a biomarker used to measure the rate of bone turnover. It provides valuable information for assessing bone health and evaluating treatment responses.
Group
Value
95% CI
Dasatinib Plus Quercetin Treatment Goup
-4.1
-28.1 – 114.6
Fisetin Treatment Group
13.7
-42.7 – 61.0
Untreated Control Group
-7.7
-42.4 – 22.5
Change in Bone Turnover MarkersSecondary· Baseline, 2 weeks
Percent change in amino-terminal propeptide of type I collagen (P1NP). The P1NP assay measures the serum concentration of the amino-terminal propeptide of type I procollagen (P1NP). As the concentration of this extension propeptide is directly proportional to the amount of new collagen laid down in bone, it can be used to assess bone formation.
Group
Value
95% CI
Dasatinib Plus Quercetin Treatment Goup
0.8
-39.6 – 113.5
Fisetin Treatment Group
-31.9
-74.0 – 23.3
Untreated Control Group
-15.2
-55.0 – 59.8
Change in Bone Turnover MarkersSecondary· Baseline, 4 weeks
Percent change in amino-terminal propeptide of type I collagen (P1NP). The P1NP assay measures the serum concentration of the amino-terminal propeptide of type I procollagen (P1NP). As the concentration of this extension propeptide is directly proportional to the amount of new collagen laid down in bone, it can be used to assess bone formation.
Group
Value
95% CI
Dasatinib Plus Quercetin Treatment Goup
4.2
-61.4 – 1480
Untreated Control Group
-12.1
-58.0 – 95.9
Change in Bone Turnover MarkersSecondary· Baseline, 20 weeks
Percent change in amino-terminal propeptide of type I collagen (P1NP). The P1NP assay measures the serum concentration of the amino-terminal propeptide of type I procollagen (P1NP). As the concentration of this extension propeptide is directly proportional to the amount of new collagen laid down in bone, it can be used to assess bone formation.
Group
Value
95% CI
Dasatinib Plus Quercetin Treatment Goup
-8.6
-48.1 – 130.9
Fisetin Treatment Group
4.5
-34.8 – 29.7
Untreated Control Group
0.1
-49.2 – 95.2
Change in Bone Mineral Density (BMD)Secondary· Baseline, 20 weeks
Percent change in BMD by dual-energy X-ray absorptiometry (DXA) at the lumbar spine, hip ((total and femoral neck (FN), and radius (total and ultra-distal)).
Lumbar Spine
Group
Value
95% CI
Dasatinib Plus Quercetin Treatment Goup
-0.2
-3.1 – 6.2
Fisetin Treatment Group
0
-1.5 – 8.9
Untreated Control Group
0.5
-10.4 – 6.8
Hip (Femoral neck )
Group
Value
95% CI
Dasatinib Plus Quercetin Treatment Goup
-0.3
-4.8 – 4.0
Fisetin Treatment Group
-0.9
-3.7 – 2.0
Untreated Control Group
-0.5
-6.0 – 19.2
Radius
Group
Value
95% CI
Dasatinib Plus Quercetin Treatment Goup
0.4
-3.0 – 6.9
Fisetin Treatment Group
0.7
-12.1 – 5.7
Untreated Control Group
0.2
-4.7 – 12.9
Change in Plasma Senescence-associated Secretory Phenotype (SASP)Secondary· Baseline, 2 weeks
Percent change in SASP cells (representing the total senescence cell burden) present. Assessment of senescence markers in bone at baseline and 2 weeks.
Group
Value
95% CI
Dasatinib Plus Quercetin Treatment Goup
-2.6
-187.7 – 16.4
Fisetin Treatment Group
-0.9
-41.8 – 3.7
Untreated Control Group
-2.5
-110.4 – 91.5
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse Events were collected from baseline to end of study, approximately 20 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Dasatinib Plus Quercetin Treatment Goup
Serious: 0/30 (0%)
Deaths: 0/30
Fisetin Treatment Group
Serious: 1/14 (7%)
Deaths: 0/14
Untreated Control Group
Serious: 0/30 (0%)
Deaths: 0/30
Serious adverse events (1 terms)
Reaction
System
Dasatinib Plus Quercetin T…
Fisetin Treatment Group
Untreated Control Group
Gastric hemorrhage
Gastrointestinal disorders
—
—
—
Other adverse events (42 terms — click to expand)
Reaction
System
Dasatinib Plus Quercetin T…
Fisetin Treatment Group
Untreated Control Group
Headache
Nervous system disorders
—
—
—
Diarrhea
Gastrointestinal disorders
—
—
—
Nausea
General disorders
—
—
—
Pain in extremity
Musculoskeletal and connective tissue disorders
—
—
—
Fatigue
General disorders
—
—
—
Constipation
Gastrointestinal disorders
—
—
—
Pain
General disorders
—
—
—
Gastroesophageal reflux disease
Gastrointestinal disorders
—
—
—
Covid
Respiratory, thoracic and mediastinal disorders
—
—
—
Vertigo
Ear and labyrinth disorders
—
—
—
Abdominal distention
Gastrointestinal disorders
—
—
—
Abdominal pain
Gastrointestinal disorders
—
—
—
Dry Mouth
Gastrointestinal disorders
—
—
—
Allergic rhinitis
Respiratory, thoracic and mediastinal disorders
—
—
—
Cough
Respiratory, thoracic and mediastinal disorders
—
—
—
Respiratory, thoracic and mediastinal disorders - other
NCT07269470 — Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly
· Phase 2
· not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction
· Phase 1
· not yet recruiting
NCT07493408 — Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of
· Phase 2
· not yet recruiting
NCT07144293 — Improving Physical Ability and Cellular Senescence Elimination in HIV
· Phase 2
· active not recruiting
NCT05751044 — HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps
· Phase 1, PHASE2
· recruiting
Other recruiting trials for Healthy
Currently open trials in the same condition.
NCT06707207 — Predicting Future Errors During Skill Performance
· recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
· Phase 1
· recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease.
· NA
· recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects
· NA
· recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
· Phase 1, PHASE2
· recruiting
Other Sundeep Khosla, M.D. trials
Trials by the same sponsor.
NCT04905277 — Atenolol for the Prevention of Osteoporosis (APO)
· Phase 2
· active not recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sundeep Khosla, M.D.
Last refreshed: 22 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04313634.